News Channels

09 Oct 2017 EDO announces next milestone for tinostamustine (EDO-S101) as first-in-human solid tumor study begins
09 Oct 2017 Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
09 Oct 2017 The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer
07 Oct 2017 Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
07 Oct 2017 PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 – a Novel, Topical Anti-VEGF Eye Drop
06 Oct 2017 Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing
06 Oct 2017 Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
06 Oct 2017 Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
06 Oct 2017 bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
06 Oct 2017 Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
06 Oct 2017 Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
06 Oct 2017 SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis
06 Oct 2017 First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
06 Oct 2017 NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
05 Oct 2017 Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
05 Oct 2017 AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis
05 Oct 2017 VITRUVIAN BioMedical Licenses New Alzheimer’s Vaccine Targeting ABeta + TAU
05 Oct 2017 Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics
05 Oct 2017 eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
05 Oct 2017 AMR Centre deal with Medivir targets superbug time-bomb

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing